TITLE

Review: Fluoxetine, orlistat, and sibutramine modestly reduce weight in type 2 diabetes

AUTHOR(S)
Norris, S.L.
PUB. DATE
January 2005
SOURCE
ACP Journal Club;Jan/Feb2005, Vol. 142 Issue 1, p18
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article reports that fluoxetine, orlistat, and sibutramine modestly reduce weight in type 2 diabetes. Published and unpublished studies in any language were selected if they used pharmacotherapy as the primary strategy for weight loss in patients greater than 18 years of age with type 2 diabetes and had weight as an outcome. In patients with type 2 diabetes mellitus, fluoxetine, orlistat and sibutramine modestly reduce weight and fluoxetine and orlistat improve blood sugar control.
ACCESSION #
15851789

 

Related Articles

  • COMMENTARY: Review: Fluoxetine, orlistat, and sibutramine modestly reduce weight in type 2 diabetes. Byrne, Christopher D.; Wild, Sarah // ACP Journal Club;Jan/Feb2005, Vol. 142 Issue 1, p18 

    The article reports that fluoxetine, orlistat, and sibutramine modestly reduce weight in type 2 diabetes. Attrition is an important issue in weight loss studies because patients who do not achieve their goal weight often do not return for follow-up. Although orlistat and sibutramine undoubtedly...

  • SSRI coverage fails to spark real debate. Norrström, Ida // New Zealand Doctor;3/12/2008, p4 

    The article reports that research on selective serotonin reuptake inhibitors (SSRIs) did not start a debate on the best use of the drugs. According to the study published in the online journal "Public Library of Science," four of the most commonly prescribed antidepressants, two of which are...

  • Antidepressant Medication Use, Weight Gain, and Risk of Type 2 Diabetes. KIVIMÄKI, MIKA; HAMER, MARK; BATTY, G. DAVID; GEDDES, JOHN R.; TABAK, ADAM G.; PENTTI, JAANA; VIRTANEN, MARIANNA; VAHTERA, JUSSI // Diabetes Care;Dec2010, Vol. 33 Issue 12, p2611 

    OBJECTIVE-- To examine antidepressant medication use as a risk factor for type 2 diabetes and weight gain. RESEARCH DESIGN AND METHODS-- A series of nested studies within a prospective cohort of 151,347 working-aged men and women including 9,197 participants with continuing antidepressant...

  • Effects of sertraline on autonomic and cognitive functions in healthy volunteers. Siepmann, Martin; Grossmann, Jens; Mück-Weymann, Michael; Kirch, Wilhelm // Psychopharmacology;2003, Vol. 168 Issue 3, p293 

    Rationale: Though sertraline, a selective serotonin reuptake inhibitor (SSRI), causes autonomic and cognitive adverse events such as dry mouth and somnolence, there is a paucity of appropriately designed studies on the cognitive and autonomic effects of the drug in the literature. Objective: To...

  • Ditch the pills.  // New Scientist;7/23/2005, Vol. 187 Issue 2509, p4 

    The article presents a study, which examines the role of antidepressants in tackling mental depression in human beings. The study was conducted by Joanna Moncrieff and Irving Kirsch, and published in the "British Medical Journal." They opine that antidepressants are no better than placebos and...

  • How do SSRIs help patients with irritable bowel syndrome? Creed, F. // Gut;Aug2006, Vol. 55 Issue 8, p1065 

    The article discusses the use of selective serotonin reuptake inhibitor (SSRI) for the treatment of depression patients with irritable bowel syndrome (IBS). In case of non-depressed IBS patients, placebo was found to be better than fluoxetine for improving the condition of patients. SSRI...

  • Human cytochromes mediating N-demethylation of fluoxetine in vitro. von Moltke, L. L.; Greenblatt, David J.; Duan, Su Xiang; Schmider, Jürgen; Wright, C. Eugene; Harmatz, Jerold S.; Shader, Richard I.; Moltke, L. L. Von // Psychopharmacology;1997, Vol. 132 Issue 4, p402 

    Abstract Biotransformation of the selective serotonin reuptake inhibitor antidepressant, fluoxetine, to its principal metabolite, norfluoxetine, was evaluated in human liver microsomes and in microsomes from transfected cell lines expressing pure human cytochromes. In human liver microsomes,...

  • The behavioral effects of sertraline, fluoxetine, and paroxetine differ on the differential-reinforcement-of-low-rate 72-second operant schedule in the rat. Sokolowski, J. D.; Seiden, L. S. // Psychopharmacology;1999, Vol. 147 Issue 2, p153 

    Abstract Rationale: Recent evidence indicates that specific serotonin (5-hydroxytryptamine; 5-HT) reuptake inhibitors (SSRIs) are not a clinically or experimentally homogeneous class of drugs. Because the differential-reinforcement-of-low-rates 72-second (DRL 72-s) operant schedule has been...

  • Pharmacogenomics as an Adjunct in Death Certification of Amitriptyline, Nortriptyline Clomipramine, and Fluoxetine.  // Journal of Analytical Toxicology;May/Jun2004, Vol. 28 Issue 4, p278 

    Presents the abstract of the study "Pharmacogenomics as an Adjunct in Death Certification of Amitriptyline, Nortriptyline Clomipramine, and Fluoxetine," by Jimmy Crockett.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics